Navidea Biopharmaceuticals Inc. (NAVB) 1.28 $NAVB
Should Navidea Biopharmaceuticals (NAVB) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:55AM CDT
Navidea Biopharmaceuticals has been overlooked by investors but it has actually seen estimates rise over the past month.
Navidea Enters Lymphoseek(R) Development and Commercialization Agreement for China
Business Wire - Thu Sep 04, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) has entered an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co., Ltd., a pharmaceutical organization with a broad China focus in oncology and other therapeutic areas, who will develop and commercialize Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection in China. In exchange, Navidea will earn revenue based on unit sales to Sinotau, a royalty based on Sinotau's sales of Lymphoseek and up to $2.5 million in milestones from Sinotau, including a $300,000 upfront payment. Lymphoseek is a novel, receptor-targeted, small-molecule radiopharmaceutical approved in the U.S. for use in lymphatic mapping to assist in the detection of lymph nodes in patients with breast cancer or melanoma and for use in guiding sentinel lymph node biopsy in certain oral cancer patients.
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc.
PR Newswire - Mon Aug 18, 8:00AM CDT
On Friday, August 15, 2014, the NASDAQ Composite ended at 4,464.93, up 0.27%, the Dow Jones Industrial Average finished the day 0.30% lower at 16,662.91, and the S&P 500 closed at 1,955.06, down 0.01%. During the session six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 716.21, up 0.11%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), Array BioPharma Inc. (NASDAQ: ARRY), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Pharmacyclics Inc. (NASDAQ: PCYC). Free research on these five companies can be accessed at:
Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million
Business Wire - Wed Aug 06, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced financial results and business highlights for the second quarter and first half of 2014. Revenue to Navidea from sales of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection grew to more than $1 million in the second quarter of 2014, an increase of 67% compared to the first quarter 2014 and an increase of over 700% compared to the second quarter of 2013 when the product was first launched. Based on the sales trends observed, Navidea reiterates its full-year 2014 Lymphoseek revenue expectation of $5 to $6 million.
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Tue Jul 29, 8:37AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens. The announcement will be followed by a conference call with the investment community, at 8:30 a.m. EDT.
Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results
Business Wire - Thu Jul 17, 2:44PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17, 2014. Approximately 79 percent of outstanding shares were represented at the meeting.
Navidea Joins Essex Woodland's Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases
Business Wire - Wed Jul 16, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has formed a joint enterprise with Essex Woodlands-backed Rheumco, LLC, to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. The joint enterprise, called R-NAV, LLC, will combine Navidea's proprietary Manocept CD206 macrophage targeting platform and Rheumco's proprietary Tin-117m radioisotope technology to focus on leveraging the platforms across several indications with high unmet medical need:
Accuray Shows Continued Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 4:25PM CDT
We are also encouraged about Accuray's (ARAY) narrower loss in the 2014-third quarter and upgraded guidance for total revenue for the full fiscal year.
Cyberonics Poised on Favorable Market Trend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 2:20PM CDT
On July 2, we issued an updated research report on Cyberonics Inc. (CYBX).
Thoratec Acquires Irish Implant Systems Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 12:40PM CDT
Thoratec Corp. (THOR) expects to enjoy long-term tax benefits from the Apica acquisition.
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014
Business Wire - Wed Jul 02, 4:06PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 from 8:00 to 9:00 am EDT in New York City.
ABIOMED Acquires Germany's Medical Device Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 12:30PM CDT
The acquisition will solidify ABIOMED's (ABMD) position in intellectual property for axial and expandable pump capabilities
Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael Goldberg, M.D., Interim Chief Executive Officer, will participate at the 9th Annual JMP Securities Healthcare Conference June 24-25, 2014 at the Westin New York Grand Central in New York City, NY. Navidea's presentation is on Tuesday, June 24, 2014 at 2:00 PM EDT.
This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the SPDR S&P Biotech Index up 39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Navidea Biopharmaceuticals Inc. Shares Briefly Spiked Lower
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...
U.S. FDA Approves Navidea Biopharmaceuticals' Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy
Business Wire - Fri Jun 13, 11:26AM CDT
--- Lymphoseek now available for multiple patient populations using existing reimbursement codes -
Biotech Stock Mailbag: Vanda, Navidea, Provectus
at The Street - Fri Jun 13, 7:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Navidea (NAVB) Worth Watching: Stock Up 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:46AM CDT
Navidea (NAVB) was a big mover last session, with shares rising over 7% on the day.
Navidea Announces Presentations Highlighting NAV4694 Beta-Amyloid, PET Imaging Agent at the German Society of Nuclear Medicine Congress
Business Wire - Wed Mar 26, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the Department of Nuclear Medicine at University Hospital of Leipzig plan presentations highlighting Navidea's PET imaging agent, NAV4694, at the German Society of Nuclear Medicine Annual Congress in Hannover, Germany, March 26-29, 2014. NAV4694 is an investigational Fluorine-18 labeled beta-amyloid imaging agent currently being evaluated in late stage clinical trials for use as an aid in differential diagnosis and to monitor progression of Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and other forms of neurodegenerative dementia.
Navidea Biopharmaceuticals Provides Update on European Marketing Authorization Application for Lymphoseek(R)
Business Wire - Wed Mar 19, 4:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that today it held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the Committee will continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.
Should Navidea Biopharmaceuticals (NAVB) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:55AM CDT
Navidea Biopharmaceuticals has been overlooked by investors but it has actually seen estimates rise over the past month.
Navidea Enters Lymphoseek(R) Development and Commercialization Agreement for China
Business Wire - Thu Sep 04, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) has entered an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co., Ltd., a pharmaceutical organization with a broad China focus in oncology and other therapeutic areas, who will develop and commercialize Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection in China. In exchange, Navidea will earn revenue based on unit sales to Sinotau, a royalty based on Sinotau's sales of Lymphoseek and up to $2.5 million in milestones from Sinotau, including a $300,000 upfront payment. Lymphoseek is a novel, receptor-targeted, small-molecule radiopharmaceutical approved in the U.S. for use in lymphatic mapping to assist in the detection of lymph nodes in patients with breast cancer or melanoma and for use in guiding sentinel lymph node biopsy in certain oral cancer patients.
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc.
PR Newswire - Mon Aug 18, 8:00AM CDT
On Friday, August 15, 2014, the NASDAQ Composite ended at 4,464.93, up 0.27%, the Dow Jones Industrial Average finished the day 0.30% lower at 16,662.91, and the S&P 500 closed at 1,955.06, down 0.01%. During the session six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 716.21, up 0.11%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), Array BioPharma Inc. (NASDAQ: ARRY), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Pharmacyclics Inc. (NASDAQ: PCYC). Free research on these five companies can be accessed at:
Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million
Business Wire - Wed Aug 06, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced financial results and business highlights for the second quarter and first half of 2014. Revenue to Navidea from sales of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection grew to more than $1 million in the second quarter of 2014, an increase of 67% compared to the first quarter 2014 and an increase of over 700% compared to the second quarter of 2013 when the product was first launched. Based on the sales trends observed, Navidea reiterates its full-year 2014 Lymphoseek revenue expectation of $5 to $6 million.
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Tue Jul 29, 8:37AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens. The announcement will be followed by a conference call with the investment community, at 8:30 a.m. EDT.
Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results
Business Wire - Thu Jul 17, 2:44PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17, 2014. Approximately 79 percent of outstanding shares were represented at the meeting.
Navidea Joins Essex Woodland's Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases
Business Wire - Wed Jul 16, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has formed a joint enterprise with Essex Woodlands-backed Rheumco, LLC, to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. The joint enterprise, called R-NAV, LLC, will combine Navidea's proprietary Manocept CD206 macrophage targeting platform and Rheumco's proprietary Tin-117m radioisotope technology to focus on leveraging the platforms across several indications with high unmet medical need:
Accuray Shows Continued Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 4:25PM CDT
We are also encouraged about Accuray's (ARAY) narrower loss in the 2014-third quarter and upgraded guidance for total revenue for the full fiscal year.
Cyberonics Poised on Favorable Market Trend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 2:20PM CDT
On July 2, we issued an updated research report on Cyberonics Inc. (CYBX).
Thoratec Acquires Irish Implant Systems Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 12:40PM CDT
Thoratec Corp. (THOR) expects to enjoy long-term tax benefits from the Apica acquisition.
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014
Business Wire - Wed Jul 02, 4:06PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 from 8:00 to 9:00 am EDT in New York City.
ABIOMED Acquires Germany's Medical Device Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 12:30PM CDT
The acquisition will solidify ABIOMED's (ABMD) position in intellectual property for axial and expandable pump capabilities
Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael Goldberg, M.D., Interim Chief Executive Officer, will participate at the 9th Annual JMP Securities Healthcare Conference June 24-25, 2014 at the Westin New York Grand Central in New York City, NY. Navidea's presentation is on Tuesday, June 24, 2014 at 2:00 PM EDT.
This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the SPDR S&P Biotech Index up 39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Navidea Biopharmaceuticals Inc. Shares Briefly Spiked Lower
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...
U.S. FDA Approves Navidea Biopharmaceuticals' Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy
Business Wire - Fri Jun 13, 11:26AM CDT
--- Lymphoseek now available for multiple patient populations using existing reimbursement codes -
Biotech Stock Mailbag: Vanda, Navidea, Provectus
at The Street - Fri Jun 13, 7:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Navidea (NAVB) Worth Watching: Stock Up 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:46AM CDT
Navidea (NAVB) was a big mover last session, with shares rising over 7% on the day.
Navidea Announces Presentations Highlighting NAV4694 Beta-Amyloid, PET Imaging Agent at the German Society of Nuclear Medicine Congress
Business Wire - Wed Mar 26, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the Department of Nuclear Medicine at University Hospital of Leipzig plan presentations highlighting Navidea's PET imaging agent, NAV4694, at the German Society of Nuclear Medicine Annual Congress in Hannover, Germany, March 26-29, 2014. NAV4694 is an investigational Fluorine-18 labeled beta-amyloid imaging agent currently being evaluated in late stage clinical trials for use as an aid in differential diagnosis and to monitor progression of Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and other forms of neurodegenerative dementia.
Navidea Biopharmaceuticals Provides Update on European Marketing Authorization Application for Lymphoseek(R)
Business Wire - Wed Mar 19, 4:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that today it held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the Committee will continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.
